Critical Contrast: PlusTherapeuticsInc . (NASDAQ:PSTV) vs. Stryker (NASDAQ:SYK)

Share on StockTwits

PlusTherapeuticsInc . (NASDAQ:PSTV) and Stryker (NYSE:SYK) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Insider and Institutional Ownership

73.0% of Stryker shares are held by institutional investors. 0.7% of PlusTherapeuticsInc . shares are held by insiders. Comparatively, 7.2% of Stryker shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares PlusTherapeuticsInc . and Stryker’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PlusTherapeuticsInc . -492.45% -546.87% -58.86%
Stryker 24.99% 25.98% 11.56%

Valuation & Earnings

This table compares PlusTherapeuticsInc . and Stryker’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PlusTherapeuticsInc . $3.67 million 1.04 -$12.63 million N/A N/A
Stryker $13.60 billion 6.08 $3.55 billion $7.31 30.24

Stryker has higher revenue and earnings than PlusTherapeuticsInc ..

Risk & Volatility

PlusTherapeuticsInc . has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Dividends

Stryker pays an annual dividend of $2.08 per share and has a dividend yield of 0.9%. PlusTherapeuticsInc . does not pay a dividend. Stryker pays out 28.5% of its earnings in the form of a dividend. Stryker has increased its dividend for 8 consecutive years.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for PlusTherapeuticsInc . and Stryker, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PlusTherapeuticsInc . 0 0 0 0 N/A
Stryker 0 5 17 0 2.77

Stryker has a consensus price target of $214.39, indicating a potential downside of 3.01%. Given Stryker’s higher probable upside, analysts clearly believe Stryker is more favorable than PlusTherapeuticsInc ..

Summary

Stryker beats PlusTherapeuticsInc . on 12 of the 14 factors compared between the two stocks.

PlusTherapeuticsInc . Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company's lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. It also engages in developing DoxoPLUS, an injectable generic PEGylated liposomal formulation of doxorubicin for the treatment of breast, ovarian, multiple myeloma, and Kaposi's sarcoma cancer. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 80 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Receive News & Ratings for PlusTherapeuticsInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PlusTherapeuticsInc . and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Associated Banc  to Release Earnings on Thursday
Associated Banc to Release Earnings on Thursday
Reliance Steel & Aluminum  Set to Announce Earnings on Thursday
Reliance Steel & Aluminum Set to Announce Earnings on Thursday
Weekly Investment Analysts’ Ratings Updates for HSBC
Weekly Investment Analysts’ Ratings Updates for HSBC
Lundin Mining Co.  Receives Average Rating of “Hold” from Brokerages
Lundin Mining Co. Receives Average Rating of “Hold” from Brokerages
United Natural Foods  Shares Gap Up  After Insider Buying Activity
United Natural Foods Shares Gap Up After Insider Buying Activity
Stock Traders Purchase Large Volume of Call Options on Logitech International
Stock Traders Purchase Large Volume of Call Options on Logitech International


 
© 2006-2019 Zolmax.